Citations

Showing 10 of 108104 citations.

Review article: an analysis of safety profiles of treatments for diarrhoea‐predominant irritable bowel syndrome
Lacy, Brian E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 8, 2018 | Volume: 48 | Issue: 8 | Pages: 817-830

10.1111/apt.14948 | PMID 30194692 Get It

SummaryBackgroundIrritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of therapies is available to manage symptoms of this common disorder.AimTo provide an overview of the safety of interventions that may be used to manage patients with diarrhoea‐predominant IBS (IBS‐D).MethodsMedline and Embase database searches (through 02 May 2018) to identify clinical studies that evaluated treatment safety and/or efficacy in adults with IBS‐D.ResultsIBS‐D treatments include dietary modification, probiotics, serotonin receptor antagonists, opioid receptor agonists and antagonists, nonsystemic antibiotics, bile acid sequestrants, antidepressants, and complementary and alternative therapies. These treatments vary in administration frequency (eg, daily; short‐course therapy) and target various pathophysiologic factors. Safety profiles vary considerably by treatment among IBS‐D therapies. The number needed to harm (defined as the number of patients treated to encounter an adverse event) was lowest (worse) for antidepressants (8.5) and highest (best) for probiotics (35), and the number needed to harm (defined as the number of patients who discontinued due to an adverse event) was lowest for tricyclic antidepressants (9) and highest for rifaximin (8971). Notable safety concerns with IBS‐D treatments include pancreatitis with eluxadoline, ischaemic colitis and serious complications of constipation with alosetron, and cardiac adverse events with loperamide and tricyclic antidepressants. Treatment decisions need to account for medication risks and adverse events for each patient.ConclusionsMultiple treatment options are now available for patients with IBS‐D. However, the safety profiles of these agents vary widely by number needed to harm value. Providers should consider both safety and efficacy of a specific intervention when determining how best to manage patients’ IBS‐D symptoms.
International Analysis of LVAD Point-of-Care Versus Plasma INR: A Multicenter Study
Schettle, Sarah , Schlöglhofer, Thomas , Zimpfer, Daniel , Salimbangon, A., Wolforth, Jennifer, Schroeder, Sarah E. , Hards, Rachel, Ritchie, Brianne M., Staley, Linda L., Pereira, Naveen L. , Kushwaha, Sudhir S. , Maltais, Simon, Stulak, John M., Ritchie, Brianne, Staley, Linda, Kushwaha, Sudhir, Schima, Heinrich , Kaufmann, Friedrich , Zimpfer, Daniel

Mayo Clinic

ASAIO Journal | September 8, 2018 | Volume: 64 | Issue: 6 | Pages: e161-e165

10.1097/mat.0000000000000845 | PMID 30199385 Get It

International normalized ratio (INR) measurements manage risks of bleeding and clotting sequelae in the population with left ventricular assist device (LVAD). Studies suggest that point-of-care (POC) INR does not significantly differ from plasma INR (P-INR) values in other patient populations, although this has not been validated in a multicenter LVAD study. We sought to determine whether POC-INR and P-INR values differ significantly in the LVAD population and reviewed patients with permanent LVAD implantation at seven institutions internationally. Our cohort comprised of 279 paired POC-INR and P-INR checks in patients supported on average 630 ± 598 days postimplant with predominately HeartWare, HeartMate II, and HeartMate III devices. The population averaged 57.9 years of age, and there were 86.7% male. We found no statistically significant difference between POC-INR and P-INR values. International normalized ratio accuracy correlated weakly with the time between INR measurements (p < 0.001). When the time difference was less than 4 hours, the difference between INR pairs was significantly lower than measurements greater than 8 hours (p = 0.006). There was no statistically significant difference when comparing paired INR values and time after implant to INR check (p = 0.43), age (p = 0.12), known coagulopathy (p = 0.12), bleeding history (p = 0.22), or thrombosis history (p = 0.34). This is the first large multicenter international study comparing POC-INR and P-INR measurements in patients with LVAD and found no statistically significant difference between either methods, particularly when measured within less than 4 hours of each other.
Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology
Lorenz, Elizabeth C. , Cosio, Fernando G., Shah, Nilay D. , Groehler, Paul N., Verdick, Jayson S., Park, Walter D. , Stegall, Mark D. , Stegall, Mark D , Park, Walter , Smith, Byron H. , Schinstock, Carrie A.

Mayo Clinic

Transplantation Direct | September 8, 2018 | Volume: 4 | Issue: 10 | Pages: e392

10.1097/txd.0000000000000824 | PMID 30498769 Get It

Background Nonadherence to immunosuppression after kidney transplant is an important contributor to graft failure. Little is known about how nonadherence changes 3 years posttransplant when Medicare coverage of immunosuppression ends and how that nonadherence impacts allograft histology. The goal of this study was to compare rates of nonadherence during posttransplant years 1 to 3 to years 3 to 5 and examine the relationship between nonadherence during years 3 to 5 and 5-year allograft histology. Methods We retrospectively analyzed 552 conventional kidney allografts in patients transplanted at our center between January 1, 1999, and June 1, 2010, who used the Mayo Clinic Specialty Pharmacy for the first 5 years posttransplant. Nonadherence was defined as less than 80% proportion of days covered. Overall adherence to immunosuppression appeared to be higher during years 3 and 5 compared to between years 1 and 3 (89.4% vs 82.9%, respectively; P < 0.0001 [paired t test]). Results Overall nonadherence during posttransplant years 3 to 5 appeared to be associated with fibrosis and inflammation on 5-year allograft biopsy but not with transplant glomerulopathy (16.9% vs 5.9%, P = 0.004; 10.4% vs 8.5%, P = 0.61, respectively). After adjusting for nonadherence to calcineurin inhibitor and prednisone therapy, only nonadherence to antimetabolite therapy remained significantly associated with 5-year fibrosis and inflammation (odds ratio, 10.6; 95% confidence interval, 1.5-76.1; P = 0.02). Conclusions Efforts to improve long-term adherence, possibly through the use of specialty pharmacies and increased adherence to antimetabolite therapy, may improve long-term allograft histology and survival, although further studies are needed to confirm these findings.
Sex Differences in Resting Metabolic Rate Among Athletes
Jagim, Andrew R. , Camic, Clayton L., Askow, Andy, Luedke, Joel, Erickson, Jacob L. , Jones, Margaret T. , Oliver, Jonathan M. , Askow, Andrew T. , Erickson, Jacob, Jagim, Andrew R , Askow, Andrew T , Kerksick, Chad M.

Mayo Clinic

Journal of Strength and Conditioning Research | September 8, 2018 | Volume: 33 | Issue: 11 | Pages: 3008-3014

10.1519/jsc.0000000000002813 | PMID 30199450 Get It

Abstract Jagim, AR, Camic, CL, Askow, A, Luedke, J, Erickson, J, Kerksick, CM, Jones, MT, and Oliver, JM. Sex differences in resting metabolic rate among athletes. J Strength Cond Res 33(11): 3008–3014, 2019—The purpose of this study was to compare differences in resting metabolic rate (RMR) between sexes in Division III National Collegiate Athletic Association (NCAA) collegiate athletes and to identify predictors of RMR. Sixty-eight male (M) (age: 20.1 ± 1.5 years; height: 181.8 ± 5.9 cm; body mass (BM): 93.7 ± 16.3 kg; and body fat%: 16.3 ± 8.6%) and 48 female (F) athletes (age: 19.4 ± 1.3 years; height: 166.5 ± 6.0 cm; BM: 63.4 ± 12.7 kg; and body fat%: 21.5 ± 6.3%) participated in a single day of testing, which included determination of RMR using indirect calorimetry and air displacement plethysmography to measure fat mass and fat-free mass (FFM). An independent-samples t -test was used to compare differences in body composition and RMR between sexes, and regression analysis was used to identify predictors of RMR. Men had a significantly higher absolute RMR (M: 2,481 ± 209 vs. F: 1,553 ± 193 kcals·d −1 ; p < 0.001), but when adjusted for BM (M: 25.6 ± 8.3 vs. F: 25.9 ± 2.5 kcals·kg −1 BM per day; p = 0.82) and FFM (M: 31.1 ± 10.6 vs. F: 33.6 ± 3.8 kcals·kg −1 FFM per day; p = 0.12), these differences became nonsignificant. Regression analysis indicated that BM in both men (β = 0.73) and women (β = 0.88) was the strongest predictor of RMR. The results of the current study indicate minimal differences in RMR between sexes among athletic populations when adjusted for BM and FFM. In the current group of athletes, BM seems to account for the largest variability in RMR.
Clonal expansion of vaccine-elicited T cells is independent of aerobic glycolysis
Klarquist, Jared , Chitrakar, Alisha , Pennock, Nathan D. , Kilgore, Augustus M. , Blain, Trevor J. , Zheng, Connie , Danhorn, Thomas , Walton, Kendra , Jiang, Li , Hunter, Christopher A. , D’Alessandro, Angelo , Kedl, Ross M , Chitrakar, Alisha , Sun, Jie

Mayo Clinic

Science Immunology | September 7, 2018 | Volume: 3 | Issue: 27 | Pages: No page available

10.1126/sciimmunol.aas9822 | PMID 30194241 Get It

T cell responses to subunit vaccination require both IL-27 and IL-15 to support an aerobic glycolysis–independent metabolic program.
Adiposity Genetic Risk Score Modifies the Association Between Blood Lead Level and Body Mass Index
Wang, Ningjian , Lu, Meng , Chen, Chi , Xia, Fangzhen , Han, Bing , Cheng, Jing , Jensen, Michael D. , Lu, Yingli , Li, Qin , Chen, Yi , Zhu, Chunfang

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 7, 2018 | Volume: 103 | Issue: 11 | Pages: 4005-4013

10.1210/jc.2018-00472 | PMID 30202913 Get It

Abstract Context Previous epidemiological studies had inconsistent results regarding the relationship between blood lead level (BLL) and adiposity. Objective We aimed to investigate the associations of BLL with body mass index (BMI) particularly using Mendelian randomization analyses and examine the interaction between obesity-predisposing genes and BLL on the associations. Design and Setting A total of 3922 participants were enrolled from 16 sites in East China in 2014 from the Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (ChiCTR-ECS-14005052, www.chictr.org.cn). We calculated the weighted BMI genetic risk score (GRS) based on 29 variants that were identified and validated in East Asians. BLL was measured by atomic absorption spectrometry. Main Outcome Measure BMI was calculated, and BMI ≥25 kg/m2 was defined as overweight. Results Multivariable logistic regression analysis demonstrated significant associations between BMI with each unit increase in lnBLL (β = 0.24; 95% CI, 0.08 to 0.40; P &lt; 0.001) and each 1-point increase in BMI-GRS (β = 0.08; 95% CI, 0.05 to 0.11; P &lt; 0.001). The causal regression coefficients of genetically determined BMI for lnBLL were −0.003 (95% CI, −0.075 to 0.070), which showed no significance. The GRS modified the association of BLL with BMI and overweight (BMI ≥25 kg/m2; P for interaction = 0.031 and 0.001, respectively). Each unit of lnBLL was associated with 63% higher odds of overweight (OR 1.63; 95% CI, 1.30 to 2.05) in the highest quartile of GRS, but no significant associations were found in the lower three quartiles. Conclusions The associations of BLL with BMI and overweight (BMI ≥25 kg/m2) were significantly modulated by BMI genetic susceptibility.
Leter to the Editor
Kane, Sunanda V.

Mayo Clinic

Inflammatory Bowel Diseases | September 7, 2018 | Volume: 25 | Issue: 5 | Pages: e52-e52

10.1093/ibd/izy287 | PMID 30202960 Get It

Irrational fear of whole‐brain radiotherapy: Are we doing our patients a disservice?
Brown, Paul D. , Gondi, Vinai

Mayo Clinic

Cancer | September 7, 2018 | Volume: 124 | Issue: 17 | Pages: 3468-3473

10.1002/cncr.31649 | PMID 30192987 Get It

The authors consider the importance of a careful, balanced review of therapeutic options with patients and the current understanding of the therapeutic ratio of whole‐brain radiotherapy in patient populations with widespread intracranial disease. The goal of reviewing these options is to provide an unbiased discussion of the potential benefits and risks of whole‐brain radiotherapy, particularly with regard to cognitive outcomes.
Alternative lengthening of telomeres, ATRX loss and H3‐K27M mutations in histologically defined pilocytic astrocytoma with anaplasia
Brosnan‐Cashman, Jacqueline A. , Allen, Sariah J. , Vizcaíno, M. Adelita , Camelo‐Piragua, Sandra , Webb, Milad, Matsushita, Marcus, Wadhwani, Nitin R. , Tabbarah, Abeer , Hamideh, Dima , Chen, Liam , Arvanitis, Leonidas , Alnajar, Hussein , Barber, John R. , Rodríguez-Velasco, Alicia, Orr, Brent A. , Heaphy, Christopher M. , Orr, Brent A , Rodríguez, Fausto J. , Giannini, Caterina , Matsushita, Marcus, Jiang, Liqun , Heaphy, Christopher M

Mayo Clinic

Brain Pathology | September 7, 2018 | Volume: 29 | Issue: 1 | Pages: 126-140

10.1111/bpa.12646 | PMID 30192422 Get It

AbstractAnaplasia may be identified in a subset of tumors with a presumed pilocytic astrocytoma (PA) component or piloid features, which may be associated with aggressive behavior, but the biologic basis of this change remains unclear. Fifty‐seven resections from 36 patients (23 M, 13 F, mean age 32 years, range 3–75) were included. A clinical diagnosis of NF1 was present in 8 (22%). Alternative lengthening of telomeres (ALT) was assessed by telomere‐specific FISH and/or CISH. A combination of immunohistochemistry, DNA sequencing and FISH were used to study BRAF, ATRX, CDKN2A/p16, mutant IDH1 p.R132H and H3‐K27M proteins. ALT was present in 25 (69%) cases and ATRX loss in 20 (57%), mostly in the expected association of ALT+/ATRX‐ (20/24, 83%) or ALT‐/ATRX+ (11/11, 100%). BRAF duplication was present in 8 (of 26) (31%). H3‐K27M was present in 5 of 32 (16%) cases, all with concurrent ATRX loss and ALT. ALT was also present in 9 (of 11) cases in the benign PA precursor, 7 of which also had ATRX loss in both the precursor and the anaplastic tumor. In a single pediatric case, ALT and ATRX loss developed in the anaplastic component only, and in another adult case, ALT was present in the PA‐A component only, but ATRX was not tested. Features associated with worse prognosis included subtotal resection, adult vs. pediatric, presence of a PA precursor preceding a diagnosis of anaplasia, necrosis, presence of ALT and ATRX expression loss. ALT and ATRX loss, as well as alterations involving the MAPK pathway, are frequent in PA with anaplasia at the time of development of anaplasia or in their precursors. Additionally, a small subset of PA with anaplasia have H3‐K27M mutations. These findings further support the concept that PA with anaplasia is a neoplasm with heterogeneous genetic features and alterations typical of both PA and diffuse gliomas.
Clarification on Uveal Melanoma Associated With Myotonic Dystrophy—Reply
Pulido, José S. , Dalvin, Lauren A. , Shields, Carol L.

Mayo Clinic

JAMA Ophthalmology | September 7, 2018 | Volume: 136 | Issue: 12 | Pages: 1427

10.1001/jamaophthalmol.2018.4184 | PMID 30193376 Get It